Get the Stockscreener App
0.3574
2.55%
0.0089
Pharmacyte Biotech Inc stock is traded at $0.3574, with a volume of 54,058.
It is up +2.55% in the last 24 hours and down -6.51% over the past month.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
See More
Previous Close:
$0.3485
Open:
$0.342
24h Volume:
54,058
Relative Volume:
0.52
Market Cap:
$3.84M
Revenue:
Net Income/Loss:
$-3.28M
P/E Ratio:
-0.3435
EPS:
-1.0406
Net Cash Flow:
$-4.80M
1W Performance:
-10.07%
1M Performance:
-6.51%
6M Performance:
-53.07%
1Y Performance:
-64.61%
1-Day Range:
$0.342
$0.3624
1-Week Range:
$0.3401
$0.4149
52-Week Range:
$0.3339
$1.51
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Name
Pharmacyte Biotech Inc
Sector
Industry
Phone
(917) 595.2850
Address
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMCB
Pharmacyte Biotech Inc
|
0.3574 | 3.84M | 0 | -3.28M | -4.80M | -1.0406 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pharmacyte Biotech Inc Stock (PMCB) Latest News
Is PharmaCyte Biotech (NASDAQ:PMCB) Stock Worth Watching Today? - kalkinemedia.com
Could PharmaCyte Biotech (NASDAQ:PMCB) Shift the Penny Stocks Story? - kalkinemedia.com
PharmaCyte (NASDAQ: PMCB) risks delisting if its stock stays below $1 - Stock Titan
PharmaCyte Biotech Inc (PMCB) Key Financial Ratios – Valuation, Profitability & More - Value Research
PharmaCyte Biotech Inc (PMCB) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
PharmaCyte Biotech Inc (PMCB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
PharmaCyte Biotech (NASDAQ: PMCB): Why Is A scheduled reporting event in Focus Now? - Kalkine Media
PMCBPharmaCyte Biotech Inc Forecast, Target Price - Finviz
PharmaCyte (PMCB) Financial Results: The Company Lists Its Latest Available Figures in the Current Update; Market Reaction: Shares Move 1.58% HigherQuarterly Profit Report - vinanet.vn
PharmaCyte (PMCB) Share-Price Review: Slides 4.80% to $0.52 at the Close; Technical Focus: Price Remains Between $0.49 Support and $0.55 Resistance in the Current UpdateEarnings Miss Risk - vinanet.vn
PMCB Q1 2026 Earnings: Clinical-Stage Biotech Posts -$0.09 EPS with No RevenueSegment Revenue Breakdown - vinanet.vn
PharmaCyte Biotech (PMCB) Climbs to $0.55 as Micro-Cap Biotech Holds Key SupportFundamentals - dars.gov.et
PharmaCyte Biotech (PMCB) Climbs to $0.55 as Micro-Cap Biotech Holds Key SupportEarnings Breakout Stocks - vinanet.vn
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PharmaCyte Biotech Inc (PMCB) Stock News Today - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.59 as Shares Dip 0.71%Change of Character - vinanet.vn
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Clinical ProgressHealthcare Earnings Report - dars.gov.et
PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary - TradingView
PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Institutional Confidence - TradingKey
PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
PharmaCyte Biotech Inc (PMCB) Balance Sheet - TradingKey
PharmaCyte Biotech Inc (PMCB) Cash Flow - TradingKey
PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.600|Chg%:-0.005 - TradingKey
PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Income Statement - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.576|Chg%:-0.024 - tradingkey.com
PMCB|PharmaCyte Biotech Inc|Price:0.611|Chg%:+0.035 - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.57 Support Amid Minimal Price MovementSMA Signal - vinanet.vn
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Revenue-less Biotech Posts Net Loss; Stock SlipsEarnings Revision Report - vinanet.vn
PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PharmaCyte Biotech (PMCB) Edges Lower Near Support; Key Levels in FocusLong Short Pair - vinanet.vn
PMCB Q1 2026 Earnings: Continued Development Costs Weigh on Results, No Revenue ReportedEarnings Season Outlook - vinanet.vn
PharmaCyte Biotech (PMCB) Slips 4% as Stock Tests Key Support Near $0.60Andrews Pitchfork - dars.gov.et
PharmaCyte Biotech (PMCB) Slips 4% as Stock Tests Key Support Near $0.60Island Reversal - careplusvn.com
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN - Moomoo
PharmaCyte Biotech (PMCB) Faces Near-Term Pressure, Testing Key Support at $0.60Tick Index - vinanet.vn
[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity - Stock Titan
PharmaCyte Biotech (PMCB) cancels erroneous stock option grant - Stock Titan
PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant - Stock Titan
PharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option grant - Stock Titan
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsDebt Free Companies - dars.gov.et
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsBox Spread - dars.gov.et
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsIceberg Order - vinanet.vn
PharmaCyte Biotech (PMCB) Slides 1.4% Near Key Support Level at $0.66Adaptive Moving Average - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader ConvictionGap Down Bounce Plays - dars.gov.et
Pharmacyte Biotech Inc Stock (PMCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pharmacyte Biotech Inc Stock (PMCB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCHECHTER JONATHAN | Director |
Jan 07 '26 |
Buy |
0.84 |
20,000 |
16,872 |
192,500 |
| Silverman Joshua | CEO and President |
Jan 06 '26 |
Buy |
0.79 |
30,000 |
23,667 |
376,250 |
| SCHECHTER JONATHAN | Director |
Jan 06 '26 |
Buy |
0.79 |
20,000 |
15,808 |
172,500 |
| Silverman Joshua | CEO and President |
Jan 05 '26 |
Buy |
0.78 |
30,000 |
23,493 |
346,250 |
| SCHECHTER JONATHAN | Director |
Jan 05 '26 |
Buy |
0.78 |
20,000 |
15,552 |
152,500 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):